Take a look back into biotech in 2025 as the year is closing - from GLP-1s to radiopharmaceuticals and neuroplastogens.
Ahead of an opt-in decision on a PCSK9 inhibitor candidate, Eli Lilly is reported to be in advanced takeover negotiations with Verve Therapeutics. AstraZeneca reveals phase 2b results with its oral ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback